Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill (2016 - 2025)

Ani Pharmaceuticals' Goodwill history spans 12 years, with the latest figure at $60.0 million for Q4 2024.

  • For Q4 2024, Goodwill changed N/A year-over-year to $60.0 million; the TTM value through Dec 2024 reached $60.0 million, changed N/A, while the annual FY2024 figure was $60.0 million, N/A changed from the prior year.
  • Goodwill for Q4 2024 was $60.0 million at Ani Pharmaceuticals, up from $28.2 million in the prior quarter.
  • Across five years, Goodwill topped out at $60.0 million in Q4 2024 and bottomed at $3.6 million in Q1 2020.
  • The 5-year median for Goodwill is $27.9 million (2021), against an average of $18.8 million.
  • The largest annual shift saw Goodwill changed 0.0% in 2020 before it soared 688.3% in 2022.
  • A 5-year view of Goodwill shows it stood at $3.6 million in 2020, then soared by 679.33% to $27.9 million in 2021, then increased by 1.15% to $28.2 million in 2022, then changed by 0.0% to $28.2 million in 2023, then surged by 112.57% to $60.0 million in 2024.
  • Per Business Quant, the three most recent readings for ANIP's Goodwill are $60.0 million (Q4 2024), $28.2 million (Q2 2023), and $28.2 million (Q1 2023).